JIM JOYCE CHAIRMAN

MY PRESENTATION CONTAINS PREDICTIONS, ESTIMATES, AND OTHER FORWARD

LOOKING STATEMENTS THAT INVOLVE RISKS AND UNCERTAINTIES, INCLUDING

WHETHER AND WHEN OUR PRODUCTS ARE SUCCESSFULLY DEVELOPED AND

INTRODUCED, MARKET ACCEPTANCE OF OUR HEMOPURIFIER AND OTHER

PRODUCT OFFERINGS, REGULATORY DELAYS, MANUFACTURING DELAYS, AND

OTHER RISKS DETAILED IN OUR SEC FILINGS ACCESSIBLE AT WWW. SEC.GOV.

Forward looking statements

Available Conference Documents

"A Platform Technology to Address

California Equity Research Initiation

WE CREATE REVOLUTIONARY

THAT ADDRESS INFECTIOUS

THE FIRST MEDICAL DEVICE TO SELECTIVELY

FILTER VIRUSES AND IMMUNOSUPPRESSIVE

PARTICLES FROM CIRCULATION

Leveraging Established

Selectively Targets the

70 TREATMENT EXPERIENCES IN

SUBSTANTIAL VIRAL LOAD

REDUCTION IN HIV AND HCV

INFECTED INDIVIDUALS

IDE ON FILE WITH THE FDA

NEXTPHARMA TECHNOLOGIES

LOI SIGNED WITH MEMBRANA

HEMOPURIFIER PROVIDES A

PIPELINE INTO THREE $ MULTI-

The Most Advanced Broad-Spectrum

Bioterror & Pandemic Threats

"The Hemopurifier is the only

strategy to address the breadth of

pathogens that could be weaponized

as agents of bioterror"

TO ACCELERATE EARLY VIRAL LOAD

REDUCTION OF HCV STANDARD OF CARE

Hepatitis-C Virus (HCV)

IN THE ABSENCE OF DRUG

5 Day HCV Treatment Studies

ONE WEEK STUDY - THREE HEMOPURIFIER

HEMOPURIFIER WITH HCV-

SOC TO ACCELERATE EARLY

VIRAL FILTRATION HAS BEEN

PROVEN TO IMPROVE HCV

Validation for Viral Filtration

Hemopurifier + Current SOC

Hemopurifier + Future Iterations of

65 drugs in competition

The Hemopurifier + HCV SOC

Enrollment has been initiated at the

Up to 6 treatments in first 3 days of SOC

Clinical endpoints include:

Immediate Virologic Response (IVR)

Rapid Virologic Response (RVR)

Early Virologic Response (EVR)

Positive outcomes trigger

OUR HEMOPURIFIER IS THE ONLY

TREATMENT STRATEGY TO ADDRESS DRUG

RESISTANT AIDS PATIENTS

Human Immunodeficiency Virus (HIV)

INDIVIDUALS HAVE TO DIE

RESPOND TO THEIR MEDS?

IN THE ABSENCE OF DRUG

HIV/AIDS Patient Data

92% reduction of viral load

Improved CD4+ T-cell %

30 DAY STUDY - THREE HEMOPURIFIER TREATMENTS PER WEEK

EXOSOMES ARE SECRETED BY

ALL TUMORS, LYMPHOMAS, &

Disrupt T-Cell Signaling

Inhibit Cytokine Production

Tumor-Secreted Exosomes

OUR HEMOPURIFIER IS THE

SOLE THERAPEUTIC STRATEGY

IMMUNSUPPRESSIVE EXOSOMES

GOAL IS TO MAXIMIZE THE

ABILITY OF THE IMMUNE

A Complementary Therapeutic

Stacking additional drug

Adding drug interaction risk

BIODEFENSE & PANDEMIC

MIRIAM PROVOST NAMED

Conceived the HomeChoice Peritoneal Dialyzer

n International Marketing Manager

n Director of Worldwide Product Planning

n Director of Advanced Product Development

Commercialized the PHD System, the first daily

home hemodialysis machine

The HomeChoice Device

HEMOPURIFIER TO DELIVER

Selected 2011 Milestone

HCV Commercialization

Approval to Initiate U.S. Studies

Clinical Partners Established in EU

Multiple Bioterror Contract/Grant

Data from multiple studies

Disclosure of collaborative partnerships

Advance Mobile/In Home Hemopurifier

CREATING REVOLUTIONARY

THAT ADDRESS INFECTIOUS

8910 UNIVERSITY CENTER LANE